Movers and SHAKERS
ProMIS Neurosciences Inc. (PMN:CA)
Advancing Novel Antibody Therapeutics for Neurodegenerative Diseases
ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody for AD; PMN350, a monoclonal antibody for AD; and PMN330, a monoclonal antibody targeting toxic prionlike forms of AßO for AD. The company is also developing prospect therapies targeting the neurotoxic form of the tau protein in AD; and superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS and frontotemporal dementia, as well as alpha synuclein in Parkinson’s disease and Lewy body dementia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Cosme Ordonez, MD, Ph.D., Senior Life Sciences Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
ProMIS Neurosciences is developing novel antibody technologies. ProMIS has the capabilities to detect "Disease Associated Epitopes" on the surface of proteins, a technology with multiple applications in medicine. The Company is advancing programs for the treatment of Alzheimer's disease, Parkinson's disease and Amyotrophic lateral sclerosis (ALS).
Development of antibody-based test for Covid-19. Recently, ProMIS announced a collaboration to develop a sensitive and specific laboratory test to detect antibodies against SARS-CoV-2, the virus causing Covid-19. Given ProMIS' experience with peptide and antibody-based technologies, we believe the Company and its collaborators will be able to develop a specific test without cross-reactivity with other viruses in the coronavirus family. Thus far, high test specificity has been...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.